473 related articles for article (PubMed ID: 32462607)
1. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
[TBL] [Abstract][Full Text] [Related]
3. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
Calverley PMA; Hoz A; Xue W; Ferguson GT; Miravitlles M
COPD; 2020 Oct; 17(5):477-484. PubMed ID: 32928003
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
[TBL] [Abstract][Full Text] [Related]
5. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
[TBL] [Abstract][Full Text] [Related]
8. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
10. Effects of baseline symptom burden on treatment response in COPD.
Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
[TBL] [Abstract][Full Text] [Related]
11. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
16. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
17. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
18. Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD.
Han MK; Ray R; Foo J; Morel C; Hahn B
NPJ Prim Care Respir Med; 2018 Aug; 28(1):32. PubMed ID: 30150639
[TBL] [Abstract][Full Text] [Related]
19. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
20. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
